Annexin announces allowance of a new U.S. Patent covering manufacturing of ANXV
Annexin Pharmaceuticals AB (publ) announces that the U.S. Patent and Trademark Office has allowed an issue of the new patent, further strengthening the intellectual property and key coverage for the Annexin ‘s therapeutic product candidate ANXV.
STOCKHOLM (22 April, 2022) - ANXV is a human Annexin A5 produced by recombinant technology in a living bacterial system. Production processes of biologic drug candidates such as ANXV are highly complex. A considerable amount of time, knowledge, efforts and investments are required to produce such proteins at a quality and quantity that are acceptable for human use. The U.S. Patent Application No. 17/332,968 entitled “PROCESS OF MANUFACTURE OF ANNEXIN V” covers the key manufacturing process steps for ANXV.
“The allowance is a final step towards granting of a patent in the USA, which is a major territory of interest for us. ANXV is soon to be given to the first patients in the USA in a Phase 2 clinical study for the potential treatment of Retinal Vein Occlusion” says Anna Frostegård, MD, PhD, Chief Scientific and Medical Officer. “This new U.S. patent will be a key part of our product protection for ANXV in a major market and an asset in partnering discussions”.
About Annexin Pharmaceuticals AB (publ)
Annexin Pharmaceuticals AB is a clinical stage biotechnology company world-leading in the Annexin A5 field for the treatment of various vascular diseases. The company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for short term treatment of patients with injuries and inflammation of the blood vessels. The company has an extensive patent portfolio for the treatment of diseases that occur due to the damage and inflammation of the blood vessels. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of ANXV.
The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company´s Certified Adviser, email certifiedadviser@redeye.se or phone +46 8 121 576 90.
For further information please visit www.annexinpharma.com or contact CEO Anders Haegerstrand at +46 707 575 50 37.
This information is information that Annexin Pharmaceuticals AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CEST on April 22, 2022